Recursion Pharmaceuticals, Inc. (RXRX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a company aims to revolutionize drug discovery by decoding biology with cutting-edge tech? Recursion Pharmaceuticals, Inc. (RXRX) is doing just that, standing out as a clinical-stage TechBio company. With a current stock price of $5.76 as of April 11, 2025, and a market cap of $2.32B, Recursion is making waves, but how exactly does it operate and generate revenue? Keep reading to explore its history, ownership, mission, and the innovative ways it's changing the future of medicine.

Recursion Pharmaceuticals, Inc. (RXRX) History

Recursion Pharmaceuticals Founding Timeline

Year established

Recursion Pharmaceuticals was established in 2013.

Original location

The company was originally located in Salt Lake City, Utah.

Founding team members

The founding team members include:

• Chris Gibson (Co-founder and CEO)
• Blake Borgeson (Co-founder and former CTO)
• Dean Li (Co-founder)

Initial capital/funding

Recursion Pharmaceuticals' initial funding included a seed round of $4.2 million in 2013. This was followed by a Series A round of $12.7 million in 2014, which helped to further develop its technology and expand its research efforts.

Recursion Pharmaceuticals' Evolution Milestones

Recursion Pharmaceuticals' Transformative Moments

• Strategic Partnerships: Forming key collaborations with companies like Bayer and Roche significantly validated Recursion's technology and provided substantial funding for research and development.
• Acquisition of Vium: The acquisition of Vium enhanced Recursion's ability to generate high-quality data and improve the efficiency of its drug discovery processes.
• Initial Public Offering (IPO): The IPO in 2021 marked a major milestone, providing the financial resources needed to scale operations and advance clinical programs.
• Focus on AI and Machine Learning: Embracing AI and machine learning as core components of its drug discovery platform has enabled Recursion to analyze vast amounts of biological data and identify promising drug candidates more effectively.

To gain more insights into the investors and motivations behind Recursion Pharmaceuticals, explore: Exploring Recursion Pharmaceuticals, Inc. (RXRX) Investor Profile: Who’s Buying and Why?

Recursion Pharmaceuticals, Inc. (RXRX) Ownership Structure

Recursion Pharmaceuticals, Inc. has a mixed ownership structure, encompassing institutional holders, individual insiders, and retail investors, reflecting a blend of investment perspectives and interests.

Recursion Pharmaceuticals, Inc.'s Current Status

As of April 2025, Recursion Pharmaceuticals, Inc. is a publicly traded company, listed on the Nasdaq Global Select Market under the ticker symbol RXRX. This status enables the company to raise capital through the issuance of stock and allows public investors to participate in the company's growth. More information about the company's financial health can be found at: Breaking Down Recursion Pharmaceuticals, Inc. (RXRX) Financial Health: Key Insights for Investors.

Recursion Pharmaceuticals, Inc.'s Ownership Breakdown

Recursion Pharmaceuticals, Inc.'s Leadership

The leadership team of Recursion Pharmaceuticals, Inc. consists of experienced individuals who steer the company's strategic direction and operations. Here are some of the key figures:

• Christopher Gibson, Ph.D.: Co-Founder & CEO
• Juergen Klenk, M.D.: President
• Michael Secora: Chief Financial Officer

Recursion Pharmaceuticals, Inc. (RXRX) Mission and Values

Recursion Pharmaceuticals is dedicated to decoding biology to revolutionize drug discovery, driven by its mission to improve lives by accelerating the discovery of medicines. The company's values are deeply rooted in innovation, collaboration, and a relentless pursuit of solutions to complex biological challenges.

Recursion Pharmaceuticals' Core Purpose

Official mission statement

Recursion Pharmaceuticals' mission statement is: 'Decode Biology to Radically Improve Lives.'

• This reflects the company's focus on using advanced technology and data science to understand complex biological systems.
• The ultimate goal is to accelerate the discovery and development of new medicines.

Vision statement

While a specific, formally declared vision statement may not be explicitly publicized, Recursion Pharmaceuticals' actions and communications suggest a vision centered on:

• Becoming the leading technology-enabled drug discovery company.
• Transforming the pharmaceutical industry through data-driven insights and automation.
• Creating a future where diseases are understood and treated more effectively and efficiently.

Company slogan/tagline

Recursion Pharmaceuticals uses the tagline 'Decoding Biology to Radically Improve Lives,' which encapsulates its core mission and vision.

To delve deeper into the financial aspects of Recursion Pharmaceuticals, explore: Breaking Down Recursion Pharmaceuticals, Inc. (RXRX) Financial Health: Key Insights for Investors

Recursion Pharmaceuticals, Inc. (RXRX) How It Works

Recursion Pharmaceuticals leverages artificial intelligence (AI) and machine learning to accelerate drug discovery by analyzing massive datasets generated from biological and chemical experiments.

Recursion Pharmaceuticals, Inc.'s Product/Service Portfolio

Recursion Pharmaceuticals, Inc.'s Operational Framework

Recursion Pharmaceuticals operates through a combination of experimental biology, automation, and computational analysis. Key aspects of their operational framework include:

• Data Generation: Utilizing the Recursion Experimental Science Infrastructure (RESI), the company conducts hundreds of experiments weekly, generating terabytes of biological data.
• Machine Learning: Applying machine learning algorithms to identify complex relationships between genes, proteins, and drug candidates within the generated data.
• Drug Discovery: Leveraging insights from machine learning models to identify potential drug candidates and predict their efficacy.
• Drug Development: Progressing promising drug candidates through preclinical and clinical trials, adhering to regulatory guidelines.
• Partnerships: Collaborating with other pharmaceutical companies to expand the application of their platform and accelerate drug discovery efforts. In 2024, Recursion partnered with NVIDIA to accelerate AI drug discovery.

Recursion Pharmaceuticals, Inc.'s Strategic Advantages

Recursion Pharmaceuticals, Inc. possesses several strategic advantages that contribute to its success in the competitive drug discovery landscape:

• Proprietary Data: The company has amassed a vast and unique dataset of cellular images and biological information, which serves as a valuable asset for training its AI models.
• Integrated Platform: The integration of automated labs, machine learning algorithms, and drug discovery capabilities into a unified platform enables efficient and data-driven drug development.
• AI Expertise: Recursion's team of AI scientists and engineers possesses deep expertise in machine learning, computer vision, and data analysis, allowing them to develop cutting-edge algorithms for drug discovery.
• Strategic Partnerships: Collaborations with leading pharmaceutical companies provide access to resources, expertise, and market opportunities, accelerating the development and commercialization of drug candidates. For example, Bayer and Recursion are working together to identify novel treatments for fibrotic diseases.
• Focus on Automation: By automating much of the experimental process, Recursion can generate data at a scale and speed that is difficult for traditional drug discovery companies to match.

To gain more insights into the company's core values and long-term objectives, explore: Mission Statement, Vision, & Core Values of Recursion Pharmaceuticals, Inc. (RXRX).

Recursion Pharmaceuticals, Inc. (RXRX) How It Makes Money

Recursion Pharmaceuticals, Inc. primarily generates revenue through collaborations with pharmaceutical and biotechnology companies, licensing its technology platform, and to a lesser extent, through government grants and other sources.

Recursion Pharmaceuticals, Inc.'s Revenue Breakdown

Recursion Pharmaceuticals, Inc.'s Business Economics

Recursion Pharmaceuticals, Inc.'s business economics are centered on leveraging its technology platform for drug discovery and development. Key aspects include:

• Technology Platform: The company's core asset is its high-dimensional biology platform, which combines automated experimentation, advanced data science, and machine learning to accelerate drug discovery.
• Collaboration Agreements: A significant portion of revenue comes from partnerships with major pharmaceutical companies. These collaborations typically involve upfront payments, research funding, and potential milestone payments and royalties on future sales of developed drugs.
• R&D Investment: A substantial portion of the company's expenses is dedicated to research and development, reflecting its focus on innovation and expanding its drug pipeline.
• Data as a Strategic Asset: The vast datasets generated by its platform enhance the efficiency and accuracy of drug discovery, creating a competitive advantage.
• Operating Expenses: Includes costs associated with research and development, as well as general and administrative functions.

Recursion Pharmaceuticals, Inc.'s Financial Performance

Recursion Pharmaceuticals, Inc.'s financial performance can be assessed through the following key points:

• Revenue Generation: The company's revenue is heavily reliant on collaboration agreements.
• Cash Position: As of the 2024 fiscal year, Recursion Pharmaceuticals, Inc. maintains a strong cash position, which is crucial for funding ongoing research and development activities.
• Operating Expenses: The company experiences considerable operating expenses due to its intensive R&D efforts.
• Net Loss: Reflecting heavy investments in R&D and platform development, Recursion Pharmaceuticals, Inc. typically reports a net loss.
• Strategic Investments: Investments in technology and infrastructure are vital for long-term growth and maintaining a competitive edge.

To gain more insights into the company's investor profile, consider reading: Exploring Recursion Pharmaceuticals, Inc. (RXRX) Investor Profile: Who’s Buying and Why?

Recursion Pharmaceuticals, Inc. (RXRX) Market Position & Future Outlook

Recursion Pharmaceuticals is striving to redefine drug discovery through its integrated technology and data-driven approach, positioning itself as a leader in the rapidly evolving biotech landscape. The company's future hinges on its ability to translate its unique platform into tangible therapeutic breakthroughs and navigate the inherent challenges of drug development.

Competitive Landscape

Opportunities & Challenges

Industry Position

Recursion Pharmaceuticals operates at the intersection of biotechnology and artificial intelligence, positioning itself as a key player in the emerging field of AI-driven drug discovery.

• The company's strength lies in its ability to generate and analyze massive amounts of biological data, which fuels its machine learning algorithms and enables the identification of novel drug candidates.
• Recursion's integrated platform, combining experimental biology, automation, and artificial intelligence, differentiates it from traditional pharmaceutical companies and other AI-driven drug discovery firms.
• As of 2024, Recursion Pharmaceuticals is focused on advancing its pipeline of therapeutic programs in areas such as oncology, neuroscience, and rare diseases.
• The company's success depends on its ability to translate its technological优势 into clinically meaningful outcomes and ultimately bring innovative therapies to patients.

To gain more insights into the investor landscape, check out: Exploring Recursion Pharmaceuticals, Inc. (RXRX) Investor Profile: Who’s Buying and Why?